Please assess the completion status of the following clinical trial:

Trial Title: A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject must provide written informed consent prior to the conduct of any study-related procedures.~2. Male or female, 18-65 years of age, inclusive.~3. Primary diagnosis of opioid dependence (DSM-IV-TR).~4. Subject is considered clinically stable by their treating healthcare provider and confirmed by the following:~   1. Subject must be on SL BPN treatment for at least 6 months.~  2. Subject must have been on a SL BPN dose of 8 mg or less daily for at least the last 90 days prior to Screening.~  3. No positive urine toxicology results for illicit opioids in the last 90 days.~5. Free from significant withdrawal symptoms (score of ≤ 5 on the Clinical Opiate Withdrawal Scale \[COWS\]), as measured at the Screening Visit.~6. Female subjects of childbearing potential must be willing to use a reliable method of contraception during the entire study (Screening Visit to Follow-Up Visit).~Exclusion Criteria:~1. Current diagnosis of Acquired Immune Deficiency Syndrome (AIDS).~2. Current diagnosis of chronic pain syndrome requiring chronic opioid treatment, or conditions associated with acute episodic flares that require opioid treatment.~3. Pregnant or lactating or planning to become pregnant during the study.~4. Hypersensitivity or allergy to ethylene vinyl acetate (EVA)-containing substances or naloxone.~5. Recent scarring or tattoos on their upper arms, or a history of keloid scarring.~6. Requires current use of agents metabolized through CYP 3A4 such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), or protease inhibitors (e.g., ritonavir, indinavir, and saquinavir).~7. History of coagulopathy within the past 90 days, and/or current anti-coagulant therapy such as warfarin.~8. Current DSM-IV-TR diagnosis for substance dependence on any other psychoactive substances other than opioids or nicotine (e.g., alcohol, cocaine).~9. Significant symptoms or other factors which in the opinion of the Investigator would preclude compliance with the protocol, subject safety, adequate cooperation in the study, or obtaining informed consent.~10. Current medical conditions such as severe respiratory insufficiency that may prevent the subject from safely participating in study.~11. Any pending legal action that could prohibit participation or compliance in the study.~12. Exposure to any investigational drug within the 8 weeks prior to Screening.~13. Aspartate aminotransferase levels ≥3 X the upper limit of normal, alanine aminotransferase levels ≥ 3 X the upper limit of normal, total bilirubin ≥ 1.5 X the upper limit of normal, or creatinine ≥ 1.5 X upper limit of normal on the Screening laboratory assessments.~14. Clinically significant low platelet count on the Screening laboratory assessments, according to the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- buprenorphine implants + placebo tablets (Type: EXPERIMENTAL): Four 80 mg Probuphine implants + daily SL placebo tablets
- buprenorphine tablets + placebo implants (Type: ACTIVE_COMPARATOR): Daily SL BPN tablets (≤8 mg/daily) + four placebo implants

Based on this trial design, predict the completion outcome and termination type (if applicable).